IONS
Ionis Pharmaceuticals IncNASDAQ
Healthcare • Biotechnology
Updated 21 hours ago
Coverage limited
Factor tilt: Anti-Value Mid Cap
$42.38-2.95%
Close Oct 13, 2026
- Market cap
- $7B
- 1 month
- -17.6%
- 3 months
- -22.6%
- 1 year
- -39.4%
- 52-week range
- $42.38$86.50
- Dividend
- No dividends on record
- Next-quarter EPS estimate
- -$0.92Quarter to Sep 30, 2026 · 8 analysts · revenue $185.5M
- Short interest
- 13.7% of float22.5M shares · settled Sep 30, 2026 · +7.7% since Sep 15, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $873.76M
- Net income
- -$564.78M
- Free cash flow
- -$558.88M
- Book value
- $439.74M
- Total debt
- $2.42B
- P/E
- —
- Price / sales
- 8×
- Price / book
- 15.9×
- FCF yield
- -8.0%
- Net margin
- -64.6%
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if IONS is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Holder IQ: MEDIUM
71 top institutions tracked
as of 2026-Q2 (filed 2026-09-23)
Last 13F trend: distributing (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: neutral
Last trade: buy 75 days ago
Red flags: 0
Largest 13-F holders · Q2 2026
514 filers reported a long position in IONS for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| FMR LLC | $2B | 24.6M | +0.3% |
| Capital World Investors | $1.7B | 21.7M | +2.3% |
| BlackRock, Inc. | $848.8M | 10.7M | +2.5% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $623.2M | 7.9M | +0.6% |
| WELLINGTON MANAGEMENT GROUP LLP | $606.7M | 7.7M | +19.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | $571.8M | 7.2M | +1.3% |
| TWO SIGMA INVESTMENTS, LP | $495.7M | 6.3M | +6.7% |
| ROYAL BANK OF CANADA | $490.2M | 6.2M | +62.6% |
| STATE STREET CORP | $343.7M | 4.3M | +8.5% |
| T. Rowe Price Investment Management, Inc. | $313.9M | 4M | -35.7% |
Get the Full Analysis for IONS
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.